Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key assessments include glomerular filtration rate, tubular function, renal plasma flow, urine output, mean arterial pressure, and various biomarkers. The trial is expected to enroll 27 heart failure patients.

"We are delighted that dosing has begun in this important Phase Ib study of CD-NP in patients with heart failure," said Peter Strumph, Chief Executive Officer of Nile. "This Mayo sponsored study, which is the fourth clinical study of CD-NP, will enable us to continue to build on our understanding of the clinical effects of CD-NP."

Results from Nile's Phase Ia study in 22 healthy volunteers were consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, preserved renal function, increased natriuresis and diuresis with minimal effect on mean arterial pressure.

In parallel with Mayo's Phase Ib study, Nile is currently dosing Phase Ib and Phase IIa studies of CD-NP in heart failure patients. The primary objective of the Phase Ib study is to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in pati
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... PRINCETON,N.J.,Nov.25/PRNewswire-FirstCall/--Phar...ticalcompanycommittedtodiscovering,developingandco...rtedfinancialresultsforthefiscalyearendedSeptember...onincash,cashequivalentsandshortterminvestments. ,...28 ,, Phase2bTrial ,, InlateNovember200...
(Date:11/25/2009)... EXTON,Pa.,Nov.25/PRNewswire/--BioTrendsResearchGr...telara report,thefirstinamulti-phasesyndicatedmar...-Biotech,sStelara,fromproductlaunchthroughthefirst...squantitativeinformationfrom75uniqueDermatologists...sassesstrialanduseofStelara,obstaclestouse,typical...
(Date:11/25/2009)... COLLEGEPARK,Md.,Nov.25/PRNewswire-USNewswire/--Re...ream-likefoamthatstopsseverebleeding,wonfirstprize...theGlobalSecurityChallenge2009,companyofficialsann...omaroundtheworld,Remedium,steampitchedtheirinventi...choolofBusiness. ,, Remedium( www.remediumtechn...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reducing risk of hospitalization in the elderly 9421 1Reducing risk of hospitalization in the elderly 9421 2NIST scientists study how to stack the deck for organic solar power 13266 1NIST scientists study how to stack the deck for organic solar power 13266 2Aurora St Lukes Healing Garden Earns LEED Certification 53167 1Aurora St Lukes Healing Garden Earns LEED Certification 53167 2
...h;The drug levosimendan did not improve,survival f...compared with a more widely-used treatment for thi...he May 2 issue of, JAMA . , Acute decompensated he...zed by inability of the heart to maintain adequate...italization worldwide,but appropriate treatment i...
...uals Reported Consistent Pain-Free,Results From At...-- Patients who suffer from,migraines frequently c...ir dissatisfaction with their medicine. New data f...gational migraine therapy,Trexima, when taken earl...s, as well as a sustained pain- free response 2-24...
Other Medicine Technology:Drug for Treatment of Heart Failure Does Not Improve Survival,Compared to More Widely-used Medication 2Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 2Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 3Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 4
(Date:11/25/2009)...SCO,Nov.25/PRNewswire/--TheBayAreaAirQualityManage...are the Air Alert forThursday,November2...nyothersolidfuel,bothindoorsandoutdoors. ,, "Co...tomorrow,"saidJackBroadbent,executiveofficeroftheA...ehealthoftheirneighborsandfellowcommunitymembersth...
(Date:11/25/2009)...discovery that grew out of a collaboration between...ffer hope to the nearly 10 million Americans who s...so known as hardening of the arteries, peripheral ...problem in which narrowed arteries reduce blood fl... flag for vascular disease, heart attack and strok...
(Date:11/25/2009)... Evaluation and treatment clinics to resum...tock (Vocus) November 25, 2009 -- Centegra Health ...and H1N1 vaccine shots at four Centegra Primary Ca...t of vaccine has arrived. The clinics are at CPC s...ry and will be open as follows: ,   Fr...
(Date:11/25/2009)...ov.25/PRNewswire/-- MISSIONSkincare ®isproudt...Jude.AspartofGNC,sannualSt.Jude ThanksandGiving ca...re,s new SUPER-C(TM)LipBalm willbedonatedtoSt.Ju...kea$1,$5or$10donationatcheckoutatoneoftheir5,000+r...1millionforSt.Judeduringtheir2009 ThanksandGiving ...
(Date:11/25/2009)...treat colorectal cancer also can reverse a rare st... therapy for the disease, researchers at Vanderbil...ntrier,s disease causes thickening of the stomach ..., as well as anemia and swelling in the feet and a...ed risk for gastric cancer. Previously, the only e...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...Apollo hospital in Ahmedabad is to collaborate wit...ncer center (CBCC), to start a new radiation thera...CC of US is to supply new radiation therapy machin...hin the hospital premises a separate unit that wil...
...ers are more prone to losing their eyesight later ... There are around 500,000 people in the UK with ... an estimated 54,000 people have the condition as ...MD Alliance UK, based on a survey of 1,023 British...
...ing modality has yet another discovery to its cred... called is a safe, non-surgical method of identify... accurate// and rapid way of diagnosing meningitis...erious brain infections such as abscesses and meni...
... report published by the Department of Veterans Af...control the cholesterol levels and provided a guid... not only bad for the heart and blood vessels, but...erol Education Month in USA, VA highlights screeni...
...Japanese Encephalitis epidemic continues to cause ...sed health officials are tight-lipped about the to...Pradesh government and yesterday admitted the drea...ical facilities in eastern Uttar Pradesh, where th...
...ents who come to the emergency room with cervical ...tected. In a study, which is published in the Ann... be useful to detect such injuries in patients ove...sible on regular x-rays. In fact, more than a thir...
Other Medicine News:Health News:High Cholesterol Can Be Controlled By Screening And Prevention 2
Random Dot "E" SO-003
Randot SO-002
Emit® Phenytoin Assay
IMMULITE Phenytoin
Medicine Products: